OpenResearchAlpha

JAMA · 10 Nov 2026

Loberamisal for Acute Ischemic Stroke

Shuya Li, Baoyu Feng, Dandan He, Xuechun Wang, Hao Li, Shuhong Xu, Hong-Qiu Gu, Xiaohua Xiao, Dan Deng, Xiaoli Wang, Aihong Guo, Hongguo Dai, Zixiao Li, Yilong Wang, Xingquan Zhao, Liping Liu, Yongjun Wang, LAIS investigators, Yongjun Wang, Dan Deng, Hongshan Song, Wen Liu, Hongguo Dai, Xiaorong Yu, Min Zhao, Bo Hu, Chuanqing Yu, Ziran Wang, Li Li, Runhui Li, Zhaohui Lai, Lixin Qu, Xiaohua Xiao, Geng Liao, Guofang Chen, Jing Guo, Xiaoli Wang, Tao Feng, Bo Liu, Fei Yi, Dong Guo, Yan Song, Baoyu Yuan, Qingcheng Yang, Xinfa Mao, Deyang Li, Aihong Guo, Nengwei Yu, Yun Xu, Rong Deng, Wenchen Yang

1
Citations
Crossref's count; others 0
0
Citations in 2026
so far
–
Leading author's h-index
no author has a profile yet
35
References
works it cites, from open citation data

Citations by database

Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.

  • Crossref1
  • OpenCitations0

Citations per year

The current year is still counting.

  • 2026 so far0

Abstract

Importance Effective neuroprotective and neuroreparative therapies for acute ischemic stroke remain limited. Loberamisal is a small-molecule compound that dually targets the postsynaptic density 95 (PSD-95) pathway and α2 γ-aminobutyric acid type α (α2-GABA A ) receptor. Objective To evaluate the efficacy and safety of intravenous loberamisal for improving functional outcomes in patients with acute ischemic stroke. Design, Setting, and Participants The Loberamisal for Acute Ischemic Stroke (LAIS) trial was a multicenter, double-blind, randomized, placebo-controlled phase 3 clinical trial conducted at 32 hospitals in China. Adults aged 18 to 80 years with acute ischemic stroke, a baseline National Institutes of Health Stroke Scale score of 7 to 20, and no prestroke disability (modified Rankin Scale score, ≤1) who presented within 48 hours of symptom onset were enrolled between July 24, 2024, and December 7, 2024, with final follow-up on April 8, 2025. Interventions Participants were randomly assigned (1:1) to receive intravenous loberamisal (40 mg) or matching placebo once daily for 10 consecutive days, in addition to standard stroke care. Main Outcomes and Measures The primary outcome was achieving a full functional outcome at 90 days, defined as a modified Rankin Scale (mRS) score of 0 to 1. Safety outcomes included adverse events, serious adverse events, and mortality. Results Among 998 randomized participants, 997 received at least 1 dose of the study drug and were included in the primary analysis (502 in the loberamisal group and 495 in the placebo group). The median age was 64 years (IQR, 57-71), 336 participants (33.7%) were women, and the median baseline NIHSS score was 8 (IQR, 7-9). At 90 days, 350 participants (69.7%) in the loberamisal group achieved an mRS score of 0 to 1 compared with 279 (56.3%) in the placebo group (relative risk, 1.24; 95% CI, 1.12-1.36; risk difference, 13.28%; 95% CI, 7.24%-19.32%). Adverse events occurred in 441 participants (87.8%) in the loberamisal group and 439 (88.7%) in the placebo group. Serious adverse events occurred in 43 participants (8.6%) in the loberamisal group and 53 (10.7%) in the placebo group. All-cause mortality occurred in 6 participants (1.2%) in the loberamisal group and 10 (2.0%) in the placebo group. Conclusions and Relevance Among patients with acute ischemic stroke treated within 48 hours of symptom onset, intravenous loberamisal, compared with placebo, resulted in a higher proportion of patients achieving full functional outcomes at 90 days. Further studies are needed to validate these findings and establish whether the benefits could extend to a broader patient population. Trial Registration ClinicalTrials.gov Identifier: NCT06517173

What the data shows

  • Crossref counts 1 citations, the most of the databases. The others count 0.

Graph

This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.

Citing paper shares an authorAuthor without a profileSize shows citations, or h-index for authors

Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.

Start with

Authors (51)

Each author's standing in QAI's scholar index: the works their ORCID iD is attached to, and for anyone whose ORCID record names a lab OpenResearch follows, their arXiv preprints matched by name and a shared co-author. Names are as printed on the paper.

ProfileMost-cited paper

Cited by 0 papers

Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.

0 shown
No citing papers for this filter.

References (35)

What it cites, from open citation data, with Crossref's record of each.

Sign in to see 15 more references

A free account opens the rest of the citing papers and references on every paper’s page.